These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 29872151)

  • 1. Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome.
    Thomsen M; Skovlund E; Sorbye H; Bolstad N; Nustad KJ; Glimelius B; Pfeiffer P; Kure EH; Johansen JS; Tveit KM; Christoffersen T; Guren TK
    Br J Cancer; 2018 Jun; 118(12):1609-1616. PubMed ID: 29872151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation.
    Das A; Kunkel M; Joudeh J; Dicker DT; Scicchitano A; Allen JE; Sarwani N; Yang Z; Kaifi J; Zhu J; Liao J; El-Deiry WS
    Cancer Biol Ther; 2015; 16(5):709-13. PubMed ID: 25806877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are high initial CEA and CA 19-9 levels associated with the presence of K-ras mutation in patients with metastatic colorectal cancer?
    Selcukbiricik F; Bilici A; Tural D; Erdamar S; Soyluk O; Buyukunal E; Demirelli F; Serdengecti S
    Tumour Biol; 2013 Aug; 34(4):2233-9. PubMed ID: 23625655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial.
    Hegewisch-Becker S; Nöpel-Dünnebacke S; Hinke A; Graeven U; Reinacher-Schick A; Hertel J; Lerchenmüller CA; Killing B; Depenbusch R; Al-Batran SE; Lange T; Dietrich G; Tannapfel A; Arnold D
    Eur J Cancer; 2018 Sep; 101():105-113. PubMed ID: 30036739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.
    Alonso-Espinaco V; Cuatrecasas M; Alonso V; Escudero P; Marmol M; Horndler C; Ortego J; Gallego R; Codony-Servat J; Garcia-Albeniz X; Jares P; Castells A; Lozano JJ; Rosell R; Maurel J
    Eur J Cancer; 2014 Jul; 50(11):1973-81. PubMed ID: 24833563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
    Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
    Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.
    Sorbye H; Dragomir A; Sundström M; Pfeiffer P; Thunberg U; Bergfors M; Aasebø K; Eide GE; Ponten F; Qvortrup C; Glimelius B
    PLoS One; 2015; 10(6):e0131046. PubMed ID: 26121270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
    Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
    Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of carcinoembryonic antigen and carbohydrate antigen 19-9 in stage IV colorectal cancer patients after R0 resection.
    Abe S; Kawai K; Ishihara S; Nozawa H; Hata K; Kiyomatsu T; Tanaka T; Watanabe T
    J Surg Res; 2016 Oct; 205(2):384-392. PubMed ID: 27664887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
    Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
    Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of RAS/BRAF Status and Prognosis of Metastatic Colorectal Cancer: Analysis of 1002 Consecutive Cases.
    Tang W; Liu Y; Ji M; Liu T; Chen Y; Zhuang A; Mao Y; Chang W; Wei Y; Ren L; Xu J
    Ann Surg Oncol; 2022 Jun; 29(6):3593-3603. PubMed ID: 35301609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer.
    Thomsen M; Kersten C; Sorbye H; Skovlund E; Glimelius B; Pfeiffer P; Johansen JS; Kure EH; Ikdahl T; Tveit KM; Christoffersen T; Guren TK
    Oncotarget; 2016 Nov; 7(46):75013-75022. PubMed ID: 27738330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precystectomy serum levels of carbohydrate antigen 19-9, carbohydrate antigen 125, and carcinoembryonic antigen: prognostic value in invasive urothelial carcinoma of the bladder.
    Ahmadi H; Djaladat H; Cai J; Miranda G; Daneshmand S
    Urol Oncol; 2014 Jul; 32(5):648-56. PubMed ID: 24680660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
    Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
    BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status.
    Thomsen M; Guren MG; Skovlund E; Glimelius B; Hjermstad MJ; Johansen JS; Kure E; Sorbye H; Pfeiffer P; Christoffersen T; Guren TK; Tveit KM
    Eur J Cancer; 2017 Aug; 81():26-35. PubMed ID: 28595137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases.
    Trevisiol C; Di Fabio F; Nascimbeni R; Peloso L; Salbe C; Ferruzzi E; Salerni B; Gion M
    Int J Biol Markers; 2006; 21(4):223-8. PubMed ID: 17177160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer.
    Louhimo J; Carpelan-Holmström M; Alfthan H; Stenman UH; Järvinen HJ; Haglund C
    Int J Cancer; 2002 Oct; 101(6):545-8. PubMed ID: 12237895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
    Spindler KL; Christensen IJ; Nielsen HJ; Jakobsen A; Brünner N
    Tumour Biol; 2015 Jun; 36(6):4301-8. PubMed ID: 25608838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma.
    Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Pahl H; Fateh-Moghadam A
    Anticancer Res; 1997; 17(4B):2935-8. PubMed ID: 9329568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
    Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
    Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.